EICHORCondition: Non-Alcoholic Fatty Liver Disease · Sponsor: Madrigal Pharmaceuticals, Inc.
A double-blind placebo controlled randomized Phase 3 study to evaluate the safety and tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching placebo. At least 100 patients will be enrolled in a 100 mg open-label arm and will include a special safety population (eg, patients with compensated NASH cirrhosis).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Central Research Associates | Birmingham, Alabama, United States | — |
| Arizona Liver Health - Chandler | Chandler, Arizona, United States | — |
| East Valley Family Physicians | Chandler, Arizona, United States | — |
| The Institute For Liver Health - Glendale | Glendale, Arizona, United States | — |
| Arizona - Desert Clinical Research | Mesa, Arizona, United States | — |
| The Institute For Liver Health - Tucson | Tucson, Arizona, United States | — |
| Adobe Gastroenterology | Tucson, Arizona, United States | — |
| Arkansas Gastroenterology | North Little Rock, Arkansas, United States | — |
| Fresno Clinical Research Center | Fresno, California, United States | — |
| National Research Institute - Huntington Park | Huntington Park, California, United States | — |
| Ruane Clinical Research Group | Los Angeles, California, United States | — |
| National Research Institute - Los Angeles | Los Angeles, California, United States | — |
+ 65 more locations — full list on the registry record.
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04197479